MK-2866 and SLU-PP-332 Interaction

Avoid
Mechanism-based 53% confidence

MK-2866 and SLU-PP-332 have a potentially harmful interaction with 53% confidence. Both MK-2866 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Half-life: Under investigation (no human PK data) Typical dose: NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) metabolic, longevity
ampk hepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Gonads
moderate
Liver
moderate
Heart
low
Pancreas
low

Shared Safety Flags

2x 2 hepatotoxic compounds (MK-2866, SLU-PP-332). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take MK-2866 with SLU-PP-332?

Combining MK-2866 with SLU-PP-332 is not recommended. Both MK-2866 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-2866 and SLU-PP-332 safe together?

This combination carries significant risk. Both MK-2866 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-2866 and SLU-PP-332?

Both MK-2866 and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-2866 and SLU-PP-332?

MK-2866 has a half-life of ~24 hours and SLU-PP-332 has a half-life of Under investigation (no human PK data). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-2866 vs SLU-PP-332

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.